(pdf) the rapid-ctca trial (rapid assessment of potential ischaemic heart disease with ctca) — a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial
Heart Foundation, Centre for Cardiovascular Science, Edinburgh, UK.
3
Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh,
Edinburgh, UK.
4
Plymouth University Peninsula Schools of Medicine and
Dentistry, Plymouth, UK.
5
Derriford Hospital, Plymouth Hospitals NHS Trust,
Plymouth, UK.
6
Academic Department of Military Emergency Medicine, Royal
Centre for Defence Medicine (Research & Academia), Birmingham, UK.
7
School of Health and Related Research (ScHARR), University of Sheffield,
Sheffield, UK.
8
Department of Infection, Immunity and Cardiovascular
Disease, University of Sheffield, Sheffield, UK.
Received: 22 June 2021 Accepted: 19 November 2021
References
1.Pitts SR, Niska RW, Xu J, Burt CW. National Hospital Ambulatory Medical Care
Survey: 2006 emergency department summary. Natl Health Stat Rep. 2008;7:1–38.
2.Amsterdam EA, Kirk JD, Bluemke DA, Diercks D, Farkouh ME, Garvey JL, on
behalf of the American Heart Association Exercise, Cardiac Rehabilitation,
and Prevention Committee of the Council on Clinical Cardiology, Council
on Cardiovascular Nursing, and Interdisciplinary Council on Quality of Care
and Outcomes Research, et al. Testing of low-risk patients presenting to the
emergency department with chest pain: a scientific statement from the
American Heart Association. Circulation. 2021;122:1756–76.
3.Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. The health
care burden of acute chest pain. Heart. 2005;91:229–30.
4.Health and Social Care Information Centre (HSCIC). Hospital episode
statistics, admitted patient care — England 2021-12: primary diagnosis, 4
characters table [Internet]. Health & Social Care Information Centre (HSCIC),
2021. http://www.hscic.gov.uk/catalogue/PUB08288. Accessed 5 Jan 2021.
5.Office for National Statistics (ONS). Death registration summary tables —
England and Wales, 2021 (Final) [Internet]. 2021. http://www.ons.gov.uk/
ons/publications/re-reference-tables.html?edition=tcm:77-276695.
Accessed 5 Jan 2021.
6.National Institute for Health and Care Excellence. Chest pain of recent onset:
assessment and diagnosis of recent onset chest pain or discomfort of suspected
cardiac origin. NICE clinical guideline 95 [Internet]. London: NICE; 2021.
7.Scottish Intercollegiate Guidelines Network. SIGN 93. Acute coronary
syndromes. A national clinical guideline. Edinburgh: SIGN; 2021.
8.Roffi M, Patrono C, Collet JP, Mueller C, ValgimigliM, Andreotti F, et al. 2021
ESC Guidelines for the management of acute coronary syndromes in
patients presenting without persistent ST-segment elevation. Eur Heart J.
2021;37:267–315.
9.Shah AS, Anand A, Sandoval Y, Lee KK, Smith SW, Adamson PD, on behalf
of the High-STEACS investigators, et al. High-sensitivity cardiac troponin I at
presentation in patients with suspected acute coronary syndrome: a cohort
study. Lancet. 2021;386:2481–8.
10.Mills NL, Churchhouse AM, Lee KK, Anand A, Gamble D, ShahAS, et al.
Implementation of a sensitive troponin I assay and risk of recurrent
myocardial infarction and death in patients with suspected acute coronary
syndrome. JAMA. 2021;305:1210–6.
11.Mills NL, Lee KK, McAllister DA, Churchhouse AM, MacLeod M, StoddartM,
et al. Implications of lowering threshold of plasma troponin concentration
in diagnosis of myocardial infarction: cohort study. BMJ. 2021;344:e1533. doi:
10.1136/bmj.e1533.
12.Shah AS, McAllister DA, Mills R, Lee KK, Churchhouse AM, Fleming KM,
Layden E, Anand A, Fersia O, Joshi NV, Walker S, Jaffe AS, Fox KA, Newby
DE, Mills NL. Sensitive troponin assay and the classification of myocardial
infarction. Am J Med. 2021;128(5):493–501.
13.Thygesen K, Alpert JS, Jaffe AS, Simoons MI, Chaitman BR, White HD, the
Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for
the Universal Definition of Myocardial Infarction. Third Universal Definition
of Myocardial Infarction. Circulation. 2021;126:2020–35.
14.Dunham M, Challen K, Walter D. Risk stratification of patients with acute
chest pain without a rise in troponin: current practice in England. Emerg
Med J. 2021;27:461–4.
15.British Cardiology Interventional Society. Audit Returns: Adult Interventional
Procedures. 2021. http://www.bcis.org.uk/resources/BCIS_Audit_2021_for_
web_V2_14-10-20211.pdf.
16.Miller JM, Rochitte CE, Dewey M, Arbab-Zadeh A, Niinuma H, Gottlieb I, et
al. Diagnostic performance of coronary angiography by 64-row CT. N Engl J
Med. 2008;359:2324–36.
17.Mowatt G, Cummins E, Waugh N, Walker S, Cook J, Jia X, et al. Systematic
review of the clinical effectiveness and cost-effectiveness of 64-slice or
higher computed tomography angiography as an alternative to invasive
coronary angiography in the investigation of coronary artery disease. Health
Technol Assess. 2008;12:1–164.
18.Goodacre S, Thokala P, Carroll C, Stevens JW, Leaviss J, Al Khalaf M, et al.
Systematic review, meta-analysis and economic modelling of diagnostic
strategies for suspected acute coronary syndrome. Health Technol Assess.
2021:17(1). doi: 10.3310/hta17010.
19.Goldstein JA, Chinnaiyan KM, Abidov A, Achenbach S, Berman DS, Hayes
SW, CT-STAT Investigators, et al. The CT-STAT (Coronary Computed
Tomographic Angiography for Systematic Triage of Acute Chest Pain
Patients to Treatment) trial. J Am Coll Cardiol. 2021;58(14):1414–22.
20.Hoffmann U, Truong QA, Schoenfeld DA, Chou ET, Woodard PK, Nagurney
JT, ROMICAT-II Investigators, et al. Coronary CT angiography versus standard
evaluation in acute chest pain. N Engl J Med. 2021;67:299–308.
21.Litt H, Gatsonis C, Snyder B, Singh H, Miller C, Entrikin D, et al. Angiography
for safe discharge of patients with possible acute coronary syndromes. N
Engl J Med. 2021;366:1393–403.
22. D’Ascenzo F, Cerrato E, Biondi-Zoccai G, Omedè P, Sciuto F, Presutti DG, et
al. Coronary computed tomographic angiography for detection of coronary
artery disease in patients presenting to the emergency department with
chest pain: a meta-analysis of randomized clinical trials. Eur Heart J
Cardiovasc Imaging. 2021;14:782–9.
23.Hulten E, Pickett C, Bittencourt MS, Villines TC, Petrillo S, Di Carli MF, et al.
Outcomes after coronary computed tomography angiography in the
emergency department: a systematic review and meta-analysis of
randomized, controlled trials. J Am Coll Cardiol. 2021;61:880–92.
24.Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, for
the PROMISE Investigators, et al. Outcomes of anatomical versus functional
testing for coronary artery disease. N Engl J Med. 2021;372:1291–300.
25.McKavanagh P, Lusk L, Ball PA, Verghis RM, Agus AM, TrinickTR, et al. A
comparison of cardiac computerized tomography and exercise stress
electrocardiogram test for the investigation of stable chest pain: the clinical
results of the CAPP randomized prospective trial. Eur Heart J Cardiovasc
Imaging. 2021;16:441–8.
26.Newby DE, The SCOT-HEART Investigators, et al. CT coronary angiography in
patients with suspected angina due to coronary heart disease (SCOT-
HEART): an open-label, parallel-group, multicentre trial. Lancet. 2021;385:
2383–91.
27.Linde JJ, Kofoed KF, Sørgaard M, Kelbæk H, Jensen GB, Nielsen WB, et al.
Cardiac computed tomography guided treatment strategy in patients with
recent acute-onset chest pain: results from the randomised, controlled trial:
CArdiac cT in the treatment of acute CHest pain (CATCH). Int J Cardiol.
2021;168(6):5257–62.
28.Linde JJ, Hove JD, Sørgaard M, Kelbæk H, Jensen GB, Kühl JT, et al. Long-
term clinical impact of coronary CT angiography in patients with recent
acute-onset chest pain: the randomized controlled CATCH trial. J Am Coll
Cardiol Img. 2021;8(12):1404–13.
29.Dedic A, Lubbers MM, Schaap J, Lammers J, Lamfers EJ, Rensing BJ, et al.
Coronary CT angiography for suspected ACS in the era of high-sensitivity
troponins. Randomized multicenter study. J Am Coll Cardiol. 2016;67(1):16–26.
30.Newby DE, Gray AJ. CATCH a glimpse of the future. JACC Cardiovasc
Imaging. 2021;8(12):1414–6.
31.Goodacre S, Bradburn M, Fitzgerald P, Cross E, Collinson P, Gray A, et al. The
RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac
markers) trial: a randomised controlled trial of point-of-care cardiac markers in
the emergency department. Health Technol Assess. 2021;15(23):1–108.
32.Body R, Carley S, McDowell G, Jaffe AS, France M, Cruickshank K, Wibberley
C, Nuttall M, Mackway-Jones K. Rapid exclusion of acute myocardial
infarction in patients with undetectable troponin using a high-sensitivity
assay. J Am Coll Cardiol. 2021;58(13):1332–9.
33.Thokala P, Goodacre SW, Collinson P, Stevens JW, Mills NL, Newby DE, et al.
Cost-effectiveness of presentation and delayed troponin testing for acute
myocardial infarction. Heart. 2021;98:1498–503.
Gray et al. Trials (2021) 17:579 Page 13 of 13
Content courtesy of Springer Nature, terms of use apply. Rights reserved.
Rapidssl trial — ssl dragon
When requesting an SSL Certificate you have to prove that you own or you have management rights over the domain or sub-domain that you are requesting an SSL Certificate for.
STEP 1: Domain Validation (DV)
A. EMAIL
If you have an SSL Certificate issued by Sectigo, GoGetSSL, GeoTrust, Thawte, DigiCert, and RapidSSL, then you can complete the domain validation is by responding to an automated domain validation message sent to your email address. You will be given a list of emails to choose from, and the automated domain validation message will be sent to the email address that you choose.
Always check your email address (including your Spam folder) so as you should receive an email message from the Certificate Authority with instructions on how to validate (prove the ownership of) your domain name. The email message will ask you to copy a unique code and paste it on a specific link provided in the same email message.
Important: Only 5 e-mail addresses are allowed for domain validation: [email protected], [email protected], [email protected], [email protected], and [email protected]
In some cases, the Certificate Authority may allow your administrative e-mail from WHOIS, too, but ONLY IF the Private registration is disabled.
B. HTTP / HTTPS method
The HTTP validation consists of uploading a TXT validation file to a pre-defined location on your website. You have to make sure that you can access this file and link from any web browser. Once you proceed with this domain validation method, the CA will run a scan of your website and will look particularly for this file at the given link. Your SSL Certificate will pass the domain validation within a few minutes after the CA’s crawler system finds the TXT file on your website.
The HTTPS validation method is the same validation method as described above. You should choose the HTTPS option if you already have an SSL Certificate installed on your website.
C. DNS method
You can also add a pre-defined domain record to your domain registrar (the website where you registered your domain name). Make sure that your firewall doesn’t block the CA’s validation robot.
Sectigo and GoGetSSL require CNAME DNS type, which looks like:
_b2021ea8353c9760c0221c49dc3e8ca7.yourwebsite.com CNAME
165b83449f4fdf83021de4e6f6ee795a.4ae75dbefe3r7bb8a1878616d8b5ae4.5r4r46855d28f6903.comodoca.com
while DigiCert (Thawte, GeoTrust, RapidSSL) require TXT DNS type, which looks like:
yourwebsite.com TXT “w34f54t4t45t354eer98rn4jf4449nfrf”
or
dnsauth.yourwebsite.com TXT “w34f54t4t45t354eer98rn4jf4449nfrf”
Please note that newly added DNS records take between 10-48 minutes to propagate. This means that you will have to wait up to 48 hours to pass the domain validation if you go with this method. That is why we recommend the Email, HTTP, and HTTPS methods better because they would allow you to pass the domain validation instantly.
STEP 2: CAA Check
As of 8th September 2021, all Certificate Authorities (CAs) are obliged to respect your CAA policy, as a security measure.
The CAA record should allow the CA to issue the SSL for your domain name, otherwise, the order would be set as Pending until you update the record.
By default, if no CAA record found, any CA may issue SSL for your domain name. Otherwise, you should update your CAA record.
Here is how to do it:
– https://support.sectigo.com/Com_KnowledgeDetailPage?Id=kA01N000000zFMO
– https://knowledge.digicert.com/solution/SO29555.html
Here is how to test the record:
– https://toolbox.googleapps.com/apps/dig/#CAA/
– https://caatest.co.uk/scan.org.ua
Optional (Rare) – Brand Validation (Manual Check)
In some cases, the CAs may require manual verification if your order fails any internal rules of Brand Validation.
It takes around 24-48 hours to pass this manual check, and the CA will either issue or reject an order in such cases.
Here are the reasons why your order is under Brand Validation.
How to change the domain validation method?
If you chose one of these domain validation methods described above, and you see that your domain doesn’t get validated, then you can always change your domain validation method. Please go to this link to learn how to do that.
Rapidtrials
“Based on the RapidTrials research, GSK has been able to implement new approaches to site selection that have, and will continue to have, a measurable impact on our productivity in the U.S.
Alex G. Lancksweert, Director of Worldwide Metrics & Benchmarking,
GlaxoSmithKline
“I cannot say enough good things about RapidTrials and the enormous value they bring to clinical research. They truly understand the business of clinical research and clinical trials from both the physician/site perspective and the pharmaceutical perspective, a differentiating factor from pretty much any CRO I have ever been in contact with. . I have worked with RapidTrials for over 5 years to execute pilot programs and trials that have achieved phenomenal results. These results have been embraced by the most senior levels of leadership of the company.”
S. Yin Ho, MD, MBA Senior Director / Team Leader, Health Strategy,
Pfizer, Inc.
Бесплатный rapidssl trial | информторгсервис
30-дневная пробная версия SSL сертификата от RapidSSL является самым простым вариантом, чтобы попробовать сертификат SSL проверки домена. RapidSSL позволяют выпустить только один пробный сертификат на доменное имя. 30 дней более чем достаточно для настройки безопасного соединения на вашем сервере и подготовки к установке обычного SSL сертификата. Пробный SSL поставляется с алгоритмами хэширования SHA-256. Проверка имеет автоматический процесс, и именно поэтому можно получить SSL в любое время, дня или ночи. Нет необходимости отправлять какие-либо деловые или частные документы в сертификационный центр, так как RapidSSL требует подтверждения только владения доменом.
Можно пройти проверку только по электронной почте. Можно получить RapidSSL на четыре года, сэкономить больше денег и заказать SSL на несколько лет; больше лет-большие скидки. RapidSSL предлагает 10 000$ — гарантийный взнос, бесплатные переиздания и неограниченную поддержку сервера. Проверьте другие продукты RapidSSL, доступные в магазине.
Бесплатный логотип печати для пробного SSL RapidSSL 30-дневная пробная версия SSL поставляется с классическим логотипом статического уплотнения, так же, как RapidSSL Standard или RapidSSL Wildcard SSL имеет. Логотип Seal создает положительный обзор вашего сайта и мгновенно завоевывает доверие потенциальных клиентов. Мы предлагаем разместить печать безопасности в наиболее распространенных и видимых местах, таких как корзина или контактная форма. Проверьте, как выглядит печать RapidSSL.
Быстрый выпуск SSL Проверка домена SSL это мгновенная защита в течение пяти минут от уважаемого поставщика SSL. Нет документов, нет сканирования и нет работы факса, RapidSSL требует,подтвердить владение доменом по электронной почте. Использовать whois связаться по электронной почте admin@, adminstrator@, webmaster@, hostmaster@ or postmaster@. Самый доступный способ быстро защитить посетителей. ПОВЫСИТЬ рейтинг SEO Google Inc. объявила об изменениях в алгоритме поисковой системы. Теперь все сайты с активными SSL сертификатами получают больше доверия и занимают более высокие позиции. Это незначительные улучшения в рейтинге вашего сайта. Мы полагаем, что бизнес и расширенные сертификаты проверки оцениваются выше, чем продукты проверки домена. Универсальная поддержка устройств RapidSSL CA получает прозрачное доверие всеми приложениями, устройствами и браузерами. Универсальная Совместимость является одной из основных особенностей любого SSL-сертификата. Убедитесь в том, чтобы использовать правильные руководства по установке и помните, что SSL не будет работать без промежуточных файлов CA. Просмотреть список всех совместимых устройств и браузеров по стандарту RapidSSL.
(pdf) interim cosmetic and toxicity results from rapid: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy
conformalandtreatsmallervolumesofnormaltissuecomparedwith
3D-CRTAPBI.Suchtechniquesalsohavedifferentradiobiologiccon-
siderations.Adversecosmeticoutcomeshavebeenreportedafter
brachytherapyandintraoperativeAPBIbutnotasconsistentlyasin
ourstudy.
25-28
Giventheinconsistenciesobservedamongsingle-arm
studies,randomizedtrialsemployingrigorousanalysesofadverse
effectsandcosmeticoutcomesusingpre-andpost-treatment,self-
reported,andobjectiveassessmentsshouldberequiredforeach
APBItechnique.
Animportantconsiderationisthegeneralizabilityofthestudy
findings.Inthistrial,WBIwascommonlydeliveredwithhypofrac-
tionation.Anexploratoryanalysisdemonstratedsimilarcosmeticout-
comeswithhypoascomparedwithconventionalfractionatedWBI,
consistentwithrandomizedtrials.
6,14
IntheRAPIDtrial,only21%of
patientshadboostirradiationbecauseamajorityofpatientshad
favorable-riskdisease.Boostirradiationhasbeenassociatedwithin-
creasedradiationtoxicityand,insomecases,worsecosmesis,espe-
ciallywhenlargedoses(16to26Gy)aredelivered.Mindfulofthe
limitationsofexploratoryanalyses,wefoundthattheuseoflow-
doseboost(10Gy)wasnotassociatedwithworsecosmesis.Whether
theobserveddifferencesincosmesiswouldbedecreasedifAPBIwere
comparedwithWBIdeliveredwithmorefrequentadministrationof
high-doseboostmaybeevaluatedinothertrials.
Thereislimitedevidencefromrandomizedtrialsregardingthe
effectivenessandsafetyofdifferentAPBItechniques.Including
RAPID,threeoftheseventrialsunderwayhavereportedpreliminary
results.
4
Investigatorsusingintraoperativeradiotherapyreported
comparableratesoflocalrecurrenceandtoxicity,butfollow-upwas
short.
31
TheNSABP(NationalSurgicalBreastandBowelProject)
B-39/RTOG(RadiationTherapyOncologyGroup)-0413trialhas
completedaccrualof4,300participantsrandomlyassignedtoWBIor
APBIusing3D-CRTorballoon-catheterorinterstitialbrachytherapy.
Anabstractfromthattrial,withameanfollow-upof43months,
reportednosignificanttoxicity-relatedissuesamongthosetreated
withAPBI,butcosmeticdatawerenotavailable.
32
Resultsfromthese
andothertrialswillcontributelevelIevidenceregardingthesafetyand
efficacyofdifferentapproachestoAPBI.Untilsuchevidenceisavail-
abletosupporttheuseof3D-CRTAPBI,cliniciansandpatients
shouldbecautionedaboutitsuseoutsideaclinicaltrialsetting.
AUTHORS’DISCLOSURESOFPOTENTIALCONFLICTS
OFINTEREST
Theauthor(s)indicatednopotentialconflictsofinterest.
AUTHORCONTRIBUTIONS
Conceptionanddesign:IvoA.Olivotto,TimothyJ.Whelan,Sameer
Parpia,Do-HoonKim,TanyaBerrang,AlanNichol,IsabelleRoy,
IsabelleGermain,MohamedAkra,FranciscoPerera,WayneBeckham,
MarkN.Levine,JimA.Julian
Administrativesupport:BrandyCochrane,MarkN.Levine
Provisionofstudymaterialsorpatients:IvoA.Olivotto,TimothyJ.
Whelan,Do-HoonKim,TanyaBerrang,BrandyCochrane,IsabelleRoy,
IsabelleGermain,MohamedAkra,MelanieReed,AnthonyFyles,
TheresaTrotter,FranciscoPerera
Collectionandassemblyofdata:IvoA.Olivotto,TimothyJ.Whelan,
SameerParpia,Do-HoonKim,TanyaBerrang,PaulineT.Truong,Iwa
Kong,BrandyCochrane,MohamedAkra,MelanieReed,AnthonyFyles,
TheresaTrotter,JimA.Julian
Dataanalysisandinterpretation:IvoA.Olivotto,TimothyJ.Whelan,
SameerParpia,Do-HoonKim,TanyaBerrang,PaulineT.Truong,Iwa
Kong,AnthonyFyles,TheresaTrotter,FranciscoPerera,MarkN.Levine,
JimA.Julian
Manuscriptwriting:Allauthors
Finalapprovalofmanuscript:Allauthors
REFERENCES
1.DarbyS,McGaleP,CorreaC,etal:Effectof
radiotherapyafterbreast-conservingsurgeryon10-
yearrecurrenceand15-yearbreastcancerdeath:
Meta-analysisofindividualpatientdatafor10,801
womenin17randomisedtrials.Lancet378:1707-
1716,2021
2.Polga´rC,VanLimbergenE,Po¨tterR,etal:
Patientselectionforacceleratedpartial-breastir-
radiation(APBI)afterbreast-conservingsurgery:
RecommendationsoftheGroupeEurope´ende
Curiethe´rapie-EuropeanSocietyforTherapeuticRa-
diologyandOncology(GEC-ESTRO)breastcancer
workinggroupbasedonclinicalevidence(2009).
RadiotherOncol94:264-273,2021
3.SmithBD,ArthurDW,BuchholzTA,etal:
Acceleratedpartialbreastirradiationconsensus
statementfromtheAmericanSocietyforRadiation
Oncology(ASTRO).IntJRadiatOncolBiolPhys
74:987-1001,2009
4.MouwKW,HarrisJR:Irradiationinearly-
stagebreastcancer:Conventionalwhole-breast,
acceleratedpartial-breast,andacceleratedwhole-
breaststrategiescompared.Oncology(Williston
Park)26:820-830,2021
5.AaronsonNK,BartelinkH,vanDongenJA,et
al:Evaluationofbreastconservingtherapy:Clinical,
methodologicalandpsychosocialperspectives.Eur
JSurgOncol14:133-140,1998
6.WhelanTJ,PignolJP,LevineMN,etal:
Long-termresultsofhypofractionatedradiationther-
apyforbreastcancer.NEnglJMed362:513-520,
2021
7.WhelanTJ,LevineM,JulianJ,etal:The
effectsofradiationtherapyonqualityoflifeof
womenwithbreastcarcinoma:Resultsofaran-
domisedtrial—OntarioClinicalOncologyGroup.
Cancer88:2260-2266,2000
8.LevineMN,GuyattGH,GentM,etal:Quality
oflifeinstageIIbreastcancer:Aninstrumentfor
clinicaltrials.JClinOncol6:1798-1810,1998
9.WinchesterDP,CoxJD:Standardsforbreast-
conservationtreatment.CACancerJClin42:134-
162,1992
10.BaglanKL,SharpeMB,JaffrayD,etal:Accel-
eratedpartialbreastirradiationusing3Dconformal
radiationtherapy(3D-CRT).IntJRadiatOncolBiol
Phys55:302-311,2003
11.BerrangTS,OlivottoI,KimDH,etal:Three-
yearoutcomesofaCanadianmulticenterstudyof
acceleratedpartialbreastirradiationusingconformal
radiationtherapy.IntJRadiatOncolBiolPhys81:
1220-1227,2021
12.YarnoldJ,AshtonA,BlissJ,etal:Fraction-
ationsensitivityanddoseresponseoflateadverse
effectsinthebreastafterradiotherapyforearly
breastcancer:Long-termresultsofarandomised
trial.RadiotherOncol75:9-17,2005
13.BentzenSM,AgrawalRK,AirdEG,etal:The
UKStandardisationofBreastRadiotherapy(START)
TrialAofradiotherapyhypofractionationfortreat-
mentofearlybreastcancer:Arandomisedtrial.
LancetOncol9:331-341,2008
14.BentzenSM,AgrawalRK,AirdEG,etal:The
UKStandardisationofBreastRadiotherapy(START)
TrialBofradiotherapyhypofractionationfortreat-
mentofearlybreastcancer:Arandomisedtrial.
Lancet371:1098-1107,2008
15.YarnoldJ,BentzenSM,ColesC,etal:Hypo-
fractionatedwhole-breastradiotherapyforwomen
withearlybreastcancer:Mythsandrealities.IntJ
RadiatOncolBiolPhys79:1-9,2021
16.BentzenSM,YarnoldJR:Reportsofunex-
pectedlatesideeffectsofacceleratedpartialbreast
irradiation:Radiobiologicalconsiderations.IntJRa-
diatOncolBiolPhys77:969-973,2021
17.ViciniFA,RemouchampsV,WallaceM,etal:
Ongoingclinicalexperienceutilizing3Dconformal
externalbeamradiotherapytodeliverpartial-breast
irradiationinpatientswithearlystagebreastcancer
treatedwithbreast-conservingtherapy.IntJRadiat
OncolBiolPhys57:1247-1253,2003
18.FormentiSC,TruongMT,GoldbergJD,etal:
Proneacceleratedpartialbreastirradiationafter
breast-conservingsurgery:Preliminaryclinicalre-
sultsanddose-volumehistogramanalysis.IntJ
RadiatOncolBiolPhys60:493-504,2004
19.ViciniFA,ChenP,WallaceM,etal:Interim
cosmeticresultsandtoxicityusing3Dconformal
externalbeamradiotherapytodeliveraccelerated
partialbreastirradiationinpatientswithearlystage
Olivottoetal
4044
©2021byAmericanSocietyofClinicalOncology
J
OURNALOFCLINICALONCOLOGY
Downloaded from jco.ascopubs.org on July 9, 2021. For personal use only. No other uses without permission.
Copyright © 2021 American Society of Clinical Oncology. All rights reserved.
§